Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612869 | 1.00 | CNR1 (0.47) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL19613191 | 1.00 | CNR1 (0.47) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL317399 | 1.00 | CNR1 (0.47) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL19613188 | 1.00 | CNR1 (0.47) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL19612868 | 1.00 | CNR1 (0.47) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL20515840 | 0.93 | PRKCA (0.51) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL317505 | 0.90 | CNR1 (0.46) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL19613155 | 0.90 | CNR1 (0.46) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL317504 | 0.90 | CNR1 (0.46) | CNR1CNR2KDM4EFASNALDH1A1 | |
| SCHEMBL19612860 | 0.90 | CNR1 (0.46) | CNR1CNR2KDM4EFASNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039742-B2 | Sn-2-monoacylglycerols and lipid malabsorption | NESTEC S.A. (CH) | 2018-08-07 | — | — | US | claimed |
| US-20170296507-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | STEPAN COMPANY | 2017-10-19 | — | — | US | claimed |
| US-20170056362-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | STEPAN COMPANY | 2017-03-02 | — | — | US | claimed |
| US-20150224079-A1 | SN-2-MONOACYLGYCEROLS AND LIPID MALABSORPTION | STEPAN COMPANY | 2015-08-13 | — | — | US | claimed |
| US-20140142169-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | NESTEC S.A. (CH) | 2014-05-22 | — | — | US | claimed |
| EP-2590644-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | Nestec S.A. (CH) | 2013-05-15 | — | — | EP | claimed |
| US-20130109753-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-05-02 | — | — | US | claimed |
| EP-2409695-A1 | Sn-2-Monoacylglycerols and lipid malabsorption | Beth Israel Deaconess Medical Center, Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2012004234-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | NESTEC S.A. (CH) | 2012-01-12 | — | — | WO | claimed |
| US-10285967-B2 | Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories | NESTEC S.A. (CH) | 2019-05-14 | — | — | US | disclosed |
| US-10039742-B2 | Sn-2-monoacylglycerols and lipid malabsorption | NESTEC S.A. (CH) | 2018-08-07 | — | — | US | disclosed |
| US-9980934-B2 | Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories | NESTEC S.A. (CH) | 2018-05-29 | — | — | US | disclosed |
| US-20170332691-A1 | NUTRITIONAL COMPOSITIONS COMPRISING SN-1 (3) MONOACYLGLYCEROLS FOR USE IN THE TREATMENT OF MALABSORPTION OR MALDIGESTION IN INFANTS OR YOUNG CHILDREN | Société des Produits Nestlé S.A. (CH) | 2017-11-23 | — | — | US | disclosed |
| US-20170296507-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | STEPAN COMPANY | 2017-10-19 | — | — | US | disclosed |
| US-9034917-B2 | Sn-2-monoacylglycerols and lipid malabsorption | NESTEC S.A. (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140142169-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | NESTEC S.A. (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2590644-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | Nestec S.A. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109753-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2409695-A1 | Sn-2-Monoacylglycerols and lipid malabsorption | Beth Israel Deaconess Medical Center, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012004234-A1 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION | NESTEC S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |